| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02011347 2012-003001-97 Details | 2017-04-06 Interventional | 3 | 67 | Ketamine Anesthesia | - - | |||
| NCT01611675 Details | 2017-04-06 Interventional | 1 | 3 | Leflunomide Vemurafenib Melanoma | Adverse Events - | |||
| NCT01480232 Details | 2017-04-06 Interventional | 2 | 345 | Nicotine Tobacco Use Dis… Nicotine Depend… Smoking Cessati… | Study has been put on clinical hold by FDA - | |||
| NCT01424033 Details | 2017-04-06 Interventional | 2/3 | 5 | Acetylcysteine N-monoacetylcys… Connective Tiss… Lung Diseases Lung Diseases, … Connective Tiss… Interstitial Lu… | Departure of study team Five subjects were consented. Study was terminated prior to conclusion due to departure of PI. | |||
| NCT00687544 Details | 2017-04-06 Interventional | 4 | 11 | Peginterferon a… Ribavirin Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… Infections HIV Infections Hepacivirus | - The study was terminated early due to low enrollment. The primary and secondary outcomes were not evaluated. A formal safety analysis was not performed for the 11 participants enrolled in the study. | |||
| NCT02527174 Details | 2017-04-05 Interventional | 1 | 0 | Cytarabine Idarubicin Leukemia Leukemia, Eryth… Leukemia, Megak… Leukemia, Monoc… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… | Volasertib no longer available - | |||
| NCT02382523 Details | 2017-04-05 Interventional | 4 | 0 | Adrenocorticotr… Glomerulonephri… Kidney Diseases Proteinuria IgA Nephropathy | There were no subjects enrolled locally on this study since it opened. Local IRB closure has
been requested. - | |||
| NCT02321384 2014-002297-36 Details | 2017-04-05 Interventional | 1 | 100 | Midazolam Ritonavir Healthy Volunte… | - - | |||
| NCT02210949 Details | 2017-04-05 Interventional | 4 | 7 | Epoetin Alfa Anemia, Iron-De… Iron Deficienci… Heart; Dysfunct… | Low inclusion rate - | |||
| NCT02058303 Details | 2017-04-05 Interventional | 4 | 90 | Bupivacaine Finger Injuries Hand Injuries Wounds and Inju… Wrist Injuries | PI leaving instutition - | |||
| NCT00588900 Details | 2017-04-05 Interventional | 2 | 5 | Cediranib Irinotecan Colorectal Neop… Colorectal Canc… | - - | |||
| NCT00360776 NCT00331591 Details | 2017-04-05 Interventional | 2 | 25 | Tipifarnib Leukemia Leukemia, Large… Leukemia, Lymph… Leukemia, Lymph… Stage III Chron… Stage IV Chroni… T-cell Large Gr… | - - | |||
| NCT02159040 Details | 2017-04-04 Interventional | 2 | 1 | Azacitidine Deferasirox Myelodysplastic… Preleukemia High Risk MDS | - No conclusion pertaining to efficacy and/or safety was drawn, only one patient was randomized to the study and their study participation was terminated prematurely due to fatal outcome of SAE.Only one patient in trial.No analysis will ever be done. | |||
| NCT01923623 Details | 2017-04-04 Interventional | 4 | 0 | Ropivacaine Ankle Fractures Fractures, Bone Ankle Fracture … | Study was redesigned and taken over by a ph.D-student - | |||
| NCT01364259 Details | 2017-04-04 Interventional | 3 | 17 | Amifostine Neuralgia Trigeminal Neur… | Patterns of practice changed and this technique is no longer used. - | |||
| NCT01173848 Details | 2017-04-04 Interventional | 3 | 19 | Cholecalciferol Ergocalciferols Vitamin D Kidney Diseases Renal Insuffici… Chronic Kidney … | - Adverse Events were not logged by study arms. Early termination of the study lead to small numbers of subjects analyzed. | |||
| NCT01607645 Details | 2017-03-31 Interventional | 2 | 7 | Azacitidine Cytarabine Decitabine Idarubicin Anemia, Refract… Anemia, Refract… Leukemia Leukemia, Eryth… Leukemia, Megak… Leukemia, Monoc… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Adult Acute Meg… Adult Acute Mon… Adult Acute Mon… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Erythrole… Adult Pure Eryt… Previously Trea… Recurrent Adult… Refractory Anem… | The study was terminated early because there were other competing protocols. Early termination due to similar competing protocol, which made statistical evaluation of primary endpoint and any meaningful evaluation of secondary time points not feasible. | |||
| NCT01090128 Details | 2017-03-31 Interventional | 1 | 27 | Albumin-Bound P… Cyclophosphamid… Doxorubicin Paclitaxel Breast Neoplasm… Stages II-III B… | Drug Manufacturer withdrew support for studies not in metastatic breast cancer - | |||
| NCT00761228 Details | 2017-03-31 Interventional | 2 | - | Apomorphine Brain Injuries Brain Injuries,… Persistent Vege… Wounds and Inju… Brain Injury | - - | |||
| NCT00698685 NCT00543283 Details | 2017-03-31 Interventional | 2 | 14 | Alemtuzumab Pentostatin Carcinoma, Rena… Hematologic Neo… Hodgkin Disease Leukemia Multiple Myelom… Hodgkin's Disea… Lymphoma | Pentostatin/alemtuzumab regimen had greater risk of graft failure. We did not meet criteria to stop the study because of nonrelapse mortality (safety endpoint). However, we stopped accrual to the study because of failure to meet minimal criteria for engraftment (efficacy endpoint). |